Related references
Note: Only part of the references are listed.Targeted immunotherapy strategies in ANCA-associated vasculitis
Xavier Puechal
JOINT BONE SPINE (2019)
361. The effect of reduced-dose oral glucocorticoids during induction of remission induction in severe ANCA-associated vasculitis
Michael Walsh et al.
RHEUMATOLOGY (2019)
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial
Rachel B. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)
Pierre Charles et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis
Alexandre Karras et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Pathophysiology of ANCA-associated Vasculitis
Turki Al-Hussain et al.
ADVANCES IN ANATOMIC PATHOLOGY (2017)
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
M. Yates et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Xavier Puechal et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3
Lynn A. Fussner et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
L. Guillevin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Renal involvement in anti-neutrophil cytoplasmic autoantibody associated vasculitis
Renato A. Sinico et al.
AUTOIMMUNITY REVIEWS (2013)
Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
Ulrich Specks et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations
Julia U. Holle et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Progress in treatment of ANCA-associated vasculitis
Rona M. Smith et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Randomized Controlled Trial
Thomas F. Hiemstra et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
Rachel B. Jones et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of Duration of Glucocorticoid Therapy on Relapse Rate in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Meta-Analysis
Michael Walsh et al.
ARTHRITIS CARE & RESEARCH (2010)
Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis.
Christian Pagnoux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force
C. Mukhtyar et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Randomized trial of plasma exchange or high-dosage Methylprednisolone as adjunctive therapy for severe renal vasculitis
David R. W. Jayne et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Share Paper
